INVESTOR ALERT: Class Action Lawsuit Against Galectin Therapeutics Inc. Filed by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP, representing investors of Galectin Therapeutics Inc. (“Galectin” or the “Company”) (NASDAQ:GALT), has filed a class action lawsuit in the United States District Court for the District of Nevada on behalf of a class (the “Class”) comprising purchasers of Galectin securities between January 6, 2014 and July 28, 2014, inclusive (the “Class Period”).

Please contact Lesley Portnoy, Esquire, at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

Galectin is a development stage company engaged in the research and development of therapies for fibrotic disease and cancer. The Complaint alleges that defendants misrepresented or failed to disclose that the Company paid a stock promotions firm for a misleading promotional campaign touting Galectin stock, and that the Company’s experimental drug GR-MD-02, which was being developed for the treatment of fatty liver disease, showed little difference from a placebo in its Phase 1 study.

If you are a member of the Class described above, you may move the Court no later than September 29, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, by toll-free telephone at (888) 773-9224 or by telephone at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.